TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages 993-1001

  Yoshino, Takayuki ^a   Mizunuma, Nobuyuki ^b   Yamazaki, Kentaro ^c   Nishina, Tomohiro ^d   Komatsu, Yoshito ^e   Baba, Hideo ^f   Tsuji, Akihito ^g   Yamaguchi, Kensei ^h   Muro, Kei ⁱ   Sugimoto, Naotoshi ^j   Tsuji, Yasushi ^k   Moriwaki, Toshikazu ^l   Esaki, Taito ^m   Hamada, Chikuma ⁿ   Tanase, Takanori ^o   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^f KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^g Kochi Health Sciences Center   (Japan)

^h SAITAMA CANCER CENTER   (Japan)

ⁱ AICHI CANCER CENTER HOSPITAL   (Japan)

^j OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^k Tonan Hospital   (Japan)

^l UNIVERSITY OF TSUKUBA   (Japan)

^m National Hospital Organization   (Japan)

ⁿ TOKYO UNIVERSITY OF SCIENCE   (Japan)

^o TAIHO PHARMACEUTICAL CO LTD   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; PLACEBO; TAS 102; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECTUM CANCER; REFRACTORY PERIOD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TRIFLURIDINE; URACIL;

EID: 84866925889     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70345-5     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Van Cutsem E, Nordlinger B, Cervantes A Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010, 21(suppl 2):v93-v97.
3. NCCN guidelines for: colon cancer (version 3.2012). 2012 National Comprehensive Cancer Network, (accessed April 26, 2012). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
5. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
6. Tanaka N, Oguchi K, Fujita R, et al. Trifluorothymidine incorporation into DNA strongly enforces the potential of TAS-102 and leads to remarkably prolonged survival of cancer patients April 15, 2012, 1783. American Association for Cancer Research, Chicago, IL, USA.
7. Dexter DL, Wolberg WH, Ansfield FJ, et al. The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res 1972, 32:247-253.
8. Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol 2000, 59:1227-1236.
9. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000, 17:277-283.
10. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004, 13:545-549.
11. Hong DS, Abbruzzese JL, Bogaard K, et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 2006, 107:1383-1390.
12. Overman MJ, Varadhachary G, Kopetz S, et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 2008, 26:445-454.
13. Overman MJ, Kopetz S, Varadhachary G, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 2008, 26:794-799.
14. Green MC, Pusztai L, Theriault LR, et al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006, 24. abstr 10576.
15. Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 2012, 107:429-434.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
17. Sheridan C EGFR inhibitors embrace KRAS. Nat Biotechnol 2008, 26:839-840.
18. Common Terminology Criteria for Adverse Events v3.0 Cancer Therapy Evaluation Program, (accessed April 20, 2009). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
19. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
21. Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011, 105:58-64.
22. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
23. Patel M, Bendell J, Mayer RJ, et al. A phase 1 dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2012, 30. abstr 3631.